abstract |
The present disclosure relates to bi-specific antibodies that specifically bind and neutralize both tumor necrosis factor a (TNFα) and interleukin-1β (IL-1β), and to the use of such bi specific antibodies for the therapeutic treatment of TNFα and IL-1β-mediated diseases and disorders. |